Boehringer Ingelheim signs option to acquire Trutino Biosciences
A pre-clinical stage biotech company, Trutino Biosciences is engaged in discovering and developing next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim has a two-pronged research